Does Blue Cross Blue Shield of Michigan Cover Jardiance?

What Jardiance Is and Why Coverage Matters

Jardiance is the brand name for empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for multiple indications. The FDA first approved empagliflozin 10 mg and 25 mg tablets for type 2 diabetes glycemic control in 2014 [1]. Subsequent approvals extended the label to include reducing cardiovascular death in adults with type 2 diabetes and established cardiovascular disease (2016), heart failure with reduced ejection fraction (2021), heart failure with preserved ejection fraction (2022), and chronic kidney disease progression (2023) [1].

Why the Price Makes Coverage Critical

The average wholesale price for Jardiance 10 mg (30 tablets) exceeds $630 per month in 2024. No FDA-approved generic is available. That price point makes insurance coverage or a manufacturer assistance program effectively mandatory for most patients.

The EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death with empagliflozin 10 mg or 25 mg versus placebo in patients with type 2 diabetes and established atherosclerotic cardiovascular disease [2]. The EMPEROR-Reduced trial (N=3,730) showed a 25% relative risk reduction in the composite of cardiovascular death or hospitalization for heart failure [3]. EMPEROR-Preserved (N=5,988) then showed a 21% relative risk reduction in the same composite endpoint across patients with heart failure and an ejection fraction above 40% [4]. These outcomes data are directly relevant to insurance coverage arguments.

FDA-Approved Indications That Affect Prior Auth

BCBS Michigan prior authorization criteria almost always mirror FDA labeling plus ADA or ACC/AHA guideline recommendations. Knowing which indication applies to your patient shapes the prior auth paperwork significantly.

| Indication | FDA Approval Year | Relevant Trial | |---|---|---| | Type 2 diabetes (glycemic control) | 2014 | EMPA-REG OUTCOME [2] | | CV death reduction in T2D + ASCVD | 2016 | EMPA-REG OUTCOME [2] | | Heart failure with reduced EF | 2021 | EMPEROR-Reduced [3] | | Heart failure with preserved EF | 2022 | EMPEROR-Preserved [4] | | Chronic kidney disease | 2023 | EMPA-KIDNEY [5] |

How BCBS Michigan Formularies Are Structured

Blue Cross Blue Shield of Michigan operates several distinct insurance products, and each has its own formulary. The major product lines include BCBS Michigan commercial PPO/HMO plans, Blue Care Network (BCN) HMO, and Blue Cross Medicare Advantage plans. Jardiance appears on all three formulary types, but the tier placement and cost-sharing rules differ.

Commercial PPO and HMO Plans

On commercial employer-sponsored plans, Jardiance typically lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier 3 copays commonly run $70 to $120 for a 30-day supply after the deductible is met. Tier 4 copays may reach $150 to $200 or higher.

Prior authorization is standard. The PA criteria for type 2 diabetes typically require:

• Documentation of a hemoglobin A1c of 7.0% or higher (or equivalent fasting glucose evidence)
• Trial of metformin at an adequate dose (usually 1,000 mg twice daily) for at least 90 days, with documented contraindication or intolerance if metformin was not used
• Prescriber attestation of type 2 diabetes diagnosis

For cardiovascular or heart failure indications, the PA criteria shift. Prescribers must document the specific FDA indication (reduced EF, preserved EF, or CKD) and often provide recent echocardiographic data or nephrology notes.

Blue Care Network (BCN) HMO

BCN uses a separate formulary from BCBS Michigan commercial. As of 2024, empagliflozin is included on the BCN formulary at Tier 3. PA requirements closely parallel the commercial criteria above. Patients in BCN plans must obtain the PA through their primary care physician or a BCN-contracted specialist; out-of-network prescribers cannot initiate the PA.

Blue Cross Medicare Advantage

Medicare Advantage plans administered by BCBS Michigan (including BCN Advantage) must follow CMS Part D formulary rules. Empagliflozin typically appears in the non-preferred drug tier (Tier 4 or Tier 5 on Medicare formularies), with cost-sharing that varies by plan benefit design. The Inflation Reduction Act of 2022 capped out-of-pocket drug costs for Medicare beneficiaries at $2,000 annually starting in 2025, which meaningfully reduces the long-term burden for patients who need Jardiance year-round [6].

Prior Authorization: What Your Doctor Needs to Submit

Prior authorization for Jardiance under BCBS Michigan is not optional on most plans. Missing documentation is the single most common reason for initial denial. Physicians and their administrative staff need to gather specific items before submitting.

Required Clinical Documentation

The PA submission for Jardiance in type 2 diabetes generally requires all of the following:

• A recent A1c result (within the past 6 months) showing inadequate glycemic control
• Documentation of metformin use with dates, dose, and duration, OR a clinical note explaining why metformin is contraindicated (eGFR <30 mL/min/1.73m², metformin intolerance, or lactic acidosis risk)
• Diagnosis code ICD-10 E11.x confirming type 2 (not type 1) diabetes
• Prescriber NPI and DEA number

For heart failure indications, submit echocardiography showing EF and NYHA class documentation. For CKD, provide eGFR and urine albumin-to-creatinine ratio (UACR). The EMPA-KIDNEY trial (N=6,609) showed empagliflozin 10 mg reduced the composite of kidney disease progression or cardiovascular death by 28% versus placebo (P<0.001), making the CKD indication clinically well-supported and relatively straightforward to document [5].

Timelines and the Appeals Process

BCBS Michigan is required by Michigan state law and CMS regulations to render a PA decision within 72 hours for standard requests and 24 hours for urgent requests. If the initial PA is denied:

1. Request a peer-to-peer review call between your physician and the BCBS medical reviewer. Denials reverse at higher rates during peer-to-peer than through written appeals alone.
2. Submit a formal Level 1 appeal with the EMPA-REG OUTCOME cardiovascular mortality data [2] and the current ADA Standards of Care 2024 language directly attached.
3. If Level 1 fails, file a Level 2 (external) appeal. Michigan's external appeal process is administered through the Michigan Department of Insurance and Financial Services.

The ADA Standards of Care in Diabetes 2024 state: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, an SGLT2 inhibitor with proven cardiovascular benefit is recommended to reduce the risk of major adverse cardiovascular events and/or heart failure hospitalization" [7]. Quoting this language directly in the appeal letter often accelerates approval.

Step Therapy Requirements and How to Overcome Them

Step therapy means the insurer requires documented failure of a cheaper drug before approving the requested agent. For Jardiance, BCBS Michigan step therapy almost universally requires metformin first. Some plans additionally require one of the following before Jardiance:

• A sulfonylurea (glipizide, glimepiride, or glyburide) trial
• A DPP-4 inhibitor (sitagliptin or alogliptin) trial

When Step Therapy Can Be Bypassed

Michigan's Health Insurance Reform law and federal mental health parity provisions create several grounds for bypassing step therapy:

• The patient has an established cardiovascular disease diagnosis (ASCVD, heart failure, or CKD) that makes Jardiance the guideline-recommended first-line add-on, not a second-step drug
• The patient experienced a clinically documented adverse event on a step drug (hypoglycemia with a sulfonylurea, for example)
• The prescriber provides peer-reviewed evidence that step therapy is clinically contraindicated for the specific patient

The ACC/AHA 2022 Guideline on Heart Failure explicitly states that SGLT2 inhibitors are recommended for patients with HFrEF to reduce hospitalization and cardiovascular mortality, independent of diabetes status [8]. That guideline language constitutes strong grounds for bypassing diabetes-based step therapy when the primary indication is heart failure.

Documenting Metformin Failure or Intolerance

Metformin is contraindicated when eGFR falls below 30 mL/min/1.73m² [9]. Intolerance (nausea, diarrhea, gastrointestinal upset despite extended-release formulation) should be documented with a clinical note that includes dose attempted, duration, and specific symptoms. A note that simply says "metformin not tolerated" without detail rarely satisfies BCBS prior auth reviewers.

Cost After Insurance and Assistance Programs

Even with coverage, Jardiance cost-sharing can strain patient budgets. Several programs reduce out-of-pocket exposure.

Manufacturer Copay Assistance

Boehringer Ingelheim and Eli Lilly co-market Jardiance and offer a copay card program. Commercially insured patients (not enrolled in Medicare, Medicaid, or any federal or state government health program) may pay as little as $10 per month for up to 24 months through the manufacturer's savings program. The card can be combined with commercial BCBS Michigan plans but cannot be used with Medicare Advantage or Medicaid.

Patient Assistance Programs

Patients who are uninsured or underinsured and meet income thresholds (generally below 400% of the federal poverty level) may qualify for Boehringer Ingelheim's Cares Foundation patient assistance program, which provides Jardiance at no cost. Applications require proof of income, a signed prescriber form, and insurance denial documentation.

Pharmacy Benefit Optimization

Some BCBS Michigan plans allow 90-day supplies through preferred mail-order pharmacies at a reduced per-unit cost compared to 30-day retail fills. For a Tier 3 drug, a 90-day mail-order supply might cost $180 to $240 versus $210 to $360 for three consecutive 30-day retail fills. The difference is modest but meaningful over 12 months.

Clinical Evidence That Strengthens Coverage Requests

Insurance reviewers and medical directors respond to outcomes data. Presenting the clinical trial evidence in the PA or appeal letter is not optional when other arguments have failed.

Cardiovascular Outcomes

EMPA-REG OUTCOME (N=7,020, median follow-up 3.1 years) showed empagliflozin reduced the primary MACE composite (cardiovascular death, nonfatal MI, nonfatal stroke) by 14% relative to placebo, and reduced cardiovascular mortality alone by 38% [2]. The number needed to treat to prevent one cardiovascular death over 3.1 years was 39.

These data support coverage for the cardiovascular death-reduction indication, which is distinct from glycemic control and often carries separate prior auth criteria.

Heart Failure Outcomes

EMPEROR-Reduced (N=3,730, median 16 months) showed empagliflozin 10 mg reduced cardiovascular death or HF hospitalization by 25% versus placebo, with an absolute risk reduction of 5.3 percentage points (P<0.001) [3]. EMPEROR-Preserved (N=5,988, median 26 months) showed a 21% relative risk reduction in the same composite (P<0.001) for patients with EF above 40% [4]. Both trials enrolled patients regardless of diabetes status, which matters for non-diabetic heart failure patients seeking coverage.

Kidney Protection

EMPA-KIDNEY (N=6,609, median 2 years) evaluated empagliflozin 10 mg in patients with CKD (eGFR 20 to <45, or eGFR 45 to <90 with UACR >200 mg/g). Empagliflozin reduced the composite of kidney disease progression or cardiovascular death by 28% versus placebo (P<0.001) [5]. The KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD recommends SGLT2 inhibitor use when eGFR is 20 mL/min/1.73m² or above [10].

The KDIGO guideline states: "We recommend treatment with an SGLT2 inhibitor for patients with type 2 diabetes and CKD who have an eGFR ≥20 mL/min/1.73m²" [10]. Attaching the KDIGO recommendation to a BCBS Michigan CKD-indication prior auth submission gives the reviewer an authoritative, guideline-based rationale that goes beyond manufacturer labeling.

ADA Guidelines and Why They Matter for BCBS Michigan Coverage Decisions

BCBS Michigan, like most commercial insurers, aligns its clinical coverage criteria with national guideline-issuing bodies. The American Diabetes Association, the American College of Cardiology, the American Heart Association, and the Heart Failure Society of America all publish recommendations that BCBS medical directors use as benchmarks.

ADA Standards of Care 2024

The ADA Standards of Care in Diabetes 2024 recommend SGLT2 inhibitors with proven cardiovascular benefit as preferred add-on therapy in type 2 diabetes when [7]:

• Established ASCVD is present
• High cardiovascular risk is documented
• Heart failure is present (reduced or preserved EF)
• CKD with albuminuria is present (UACR above 30 mg/g)

These are not optional enhancements to diabetes care in the ADA framework. They are Category A recommendations based on multiple large randomized controlled trials [7]. Framing the prior auth this way shifts the conversation from "does the patient need a brand drug" to "is the plan complying with standard of care."

ACC/AHA Heart Failure Guideline 2022

The 2022 ACC/AHA/HFSA Guideline for Heart Failure assigns SGLT2 inhibitors a Class I recommendation (strongest level) for patients with HFrEF to reduce HF hospitalization and cardiovascular mortality [8]. A Class I recommendation means the guideline authors concluded that benefits substantially outweigh risks and that therapy should be administered. Insurers who deny coverage for a Class I-recommended therapy face meaningful appeal and regulatory risk.

What to Do If BCBS Michigan Denies Jardiance Coverage

A denial is not a final answer. Roughly 40% to 60% of prior authorization denials that reach the peer-to-peer or formal appeal stage are overturned when properly supported by clinical documentation, according to published analyses of commercial insurer appeal outcomes [11].

Step-by-Step Action Plan

1. Request the specific denial reason in writing. BCBS Michigan is required to provide it.
2. Identify whether the denial is for step therapy failure, lack of medical necessity, or a formulary exclusion.
3. For step therapy denials, document clinical reasons the step drug is inappropriate (CV risk, intolerance, contraindication).
4. For medical necessity denials, attach trial data (EMPA-REG OUTCOME [2], EMPEROR-Reduced [3], or EMPA-KIDNEY [5] as applicable) and the relevant guideline recommendation.
5. Submit a formal written appeal within the BCBS Michigan appeal window (typically 180 days from denial).
6. If internal appeals fail, file an external appeal through the Michigan Department of Insurance and Financial Services, or contact a patient advocate.

Pharmacy-Level Alternatives While Appealing

While an appeal is pending, several short-term options reduce cost burden:

• Use the Boehringer Ingelheim manufacturer sample or a 14-day bridge supply if the prescriber has samples available.
• Apply the manufacturer copay card at a commercial pharmacy to cap out-of-pocket cost at $10 per month while the appeal proceeds.
• Ask whether dapagliflozin (Farxiga) or canagliflozin (Invokana) appear on a lower BCBS Michigan tier. Both are SGLT2 inhibitors with their own cardiovascular and renal outcomes trial data (DAPA-HF [12] and CREDENCE [13] respectively), and your physician may determine one is clinically appropriate while the Jardiance appeal is active.

DAPA-HF (N=4,744) showed dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% versus placebo in patients with HFrEF, regardless of diabetes status [12]. CREDENCE (N=4,401) showed canagliflozin 100 mg reduced the composite renal and cardiovascular outcome by 30% versus placebo in patients with type 2 diabetes and CKD [13]. Either trial provides coverage-supporting evidence if the treating physician switches to an alternative SGLT2 inhibitor.

Special Populations and Coverage Nuances

Pediatric Patients

The FDA approved empagliflozin for type 2 diabetes in patients age 10 and older in December 2023 [1]. BCBS Michigan prior auth criteria for pediatric patients are not yet uniformly defined across all plan products. Pediatric endocrinology documentation from a BCN or BCBS-contracted specialist strengthens these requests substantially.

Patients Transitioning From Medicaid to Commercial Coverage

Michigan Medicaid (Healthy Michigan Plan) maintains its own Preferred Drug List. Empagliflozin has appeared on Michigan Medicaid formularies subject to PA, but tier placement and criteria differ from BCBS commercial. Patients transitioning from Medicaid to a BCBS commercial plan should expect to restart the PA process and may not be able to transfer a prior Medicaid approval.

Pregnancy and Jardiance

The FDA label for empagliflozin includes a warning against use during the second and third trimesters due to potential adverse renal effects on the developing fetus [1]. BCBS Michigan will not cover Jardiance for a pregnant patient under standard criteria. ACOG guidelines for gestational and pre-existing diabetes in pregnancy do not include SGLT2 inhibitors [14].